Low-molecular-weight heparin in pediatric patients

Seminars in Thrombosis and Hemostasis

Volumn 30, Issue SUPPL. 1, 2004, Pages 31-39

  Sutor, Anton Heinz ^a   Chan, Anthony K C ^b   Massicotte, Patricia ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b MCMASTER UNIVERSITY   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Children; Low molecular weight heparins (LMWHS); Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ASPARAGINASE; BLOOD CLOTTING FACTOR 10A; CORTICOSTEROID; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PROTAMINE SULFATE; REVIPARIN; TINZAPARIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; BLEEDING; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; COLLATERAL CIRCULATION; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIAGNOSTIC IMAGING; DRUG EFFICACY; DRUG SAFETY; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INCIDENCE; OSTEOPENIA; PHLEBOTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; THROMBUS;

EID: 1842608582     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-823001     Document Type: Conference Paper

References (56)

1. Nowak-Göttl U, Heinecke A, von Kries R, Nürnberger W, Münchow N, Junker R. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 2001;103:165-172
2. Mitchell L, Sutor A, Andrew M. Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment. Semin Thromb Hemost 1995;21: 390-401
3. Mitchell LG, the PARKAA Investigators. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase. Cancer 2003;97:508-516
4. Sutor AH, Weissbach G, Schreiber R, Bruhn HD, Seifried E. Thrombosen im Kindesalter. Hämostaseologie 1992;12:82-93
5. van Ommen CH, Heijboer H, Büller HR, Hirasing RA, Heijmans HS, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr 2001;139:676-681
6. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994;83:1251-1257
7. Nowak-Göttl U, von Kries R, Göbel U. Neonatal symptomatic thromboembolism in Germany: two year survey. Arch Dis Child Fetal Neonatal Ed 1997;76:F163-F167
8. Sutor AH, Engelhardt W, Mehrain S, Uhl M, Zurborn DH. Anticoagulation in thrombosis of childhood: Present state. In Sutor AH, ed. Anticoagulation in Thrombosis of Childhood-English Summary of the Present State. Stuttgart, Germany: Schattauer; 1997:293-335
9. Kurekci AE, Gokce H, Yilmaz E, Akar N. The importance of factor VIII levels in childhood thrombosis. Thromb Haemost 2001;(suppl):1451 (abst)
10. Nowak-Göttl U, Kosch A, Schlegel N. Thromboembolism in newborns, infants and children. Thromb Haemost 2001;86:464-474
11. Sutor AH, Uhl M. Diagnosis of thromboembolic disease during infancy and childhood. Semin Thromb Hemost 1997;23:237-246
12. Male C, Chait P, Gineberg JS, et al. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Prophylactic Antithrombin Replacement in Kids with ALL treated with asparaginase. Thromb Haemost 2002;87:593-598
13. Sutor A H. Screening children with thrombosis for thrombophilic proteins. Cui bono? J Thromb Haemost 2003;1:886-888
14. Monaglè P, Adams M, Mahoney M, et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res 2000;47:763-766
15. Monagle P, Michelson AD, Bovill E, Andrew M. Antithrombotic therapy in children. Chest 2001;119:344S-370S
16. Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics 1995;96:939-943
17. Marzinotto V, Choi M, Massicotte MP, Chan AKC, Andrew M. Post-thrombotic syndrome in children with previous deep vein thrombosis. Thromb Haemost 2001;(suppl):OC962 (abst)
18. Lanthier S, Carmant L, David M, Larbrisseau A, de Veber G. Stroke in children: the coexistence of multiple risk factors predicts poor outcome. Neurology 2000;54:371-378
19. deVeber G, Andrew M. Cerebral sinovenous thrombosis in children. N Engl J Med 2001;345:417-423
20. Richardson MW, Allen GA, Monahan PE. Thrombosis in children: current perspective and distinct challenges. Thromb Haemost 2002;88:900-911
21. Herrmann R, Schmidmaier G, Markl B, et al. Antithrombogenic coating of stents using a biodegradable drug delivery technology. Thromb Haemost 1999;82:51-57
22. Klement P, Du YJ, Berry L, Andrew M, Chan AK. Blood-compatible biomaterials by surface coating with a novel antithrombin-heparin covalent complex. Biomaterials 2002;23:527-535
23. Sutor AH. Thrombocytosis in childhood. Semin Thromb Hemost 1995;21:330-339
24. Chan KW, Kaikov Y, Wadsworth LD. Thrombocytosis in childhood: a survey of 94 patients. Pediatrics 1989;84:1064-1067
25. Massicotte P, Julian J, Webber C, Charpentier K. Osteoporosis: a potential complication of long term warfarin therapy. Thromb Haemost 1999;(suppl):1333a (abst)
26. Shaughnessy SG, Young E, Deschamps P, Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 1995;86:1368-1373
27. Severin T, Sutor AH. Heparin-induced thrombocytopenia in pediatrics. Semin Thromb Hemost 2001;27:293-299
28. Schmugge M, Risch L, Huber AR, Benn A, Fischer JE. Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients. Pediatrics 2002;109E10 (abst)
29. Fareed J, Hoppensteadt DA, Bick RL. An update on heparins at the beginning of the new millennium. Semin Thromb Hemost 2000;26(suppl 1):5-21
30. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-698
31. Andrew M, Marzinotto V, Massicotte P, et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res 1994;35:78-83
32. Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996;128:313-318
33. Dix D, Andrew M, Marzinotto V, et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 2000;136:439-145
34. Kuhle S, Massicotte MP, Andrew M, et al. A dose-finding study of tinzaparin in pediatric patients. Blood 2002;100:279a
35. Nohe N, Kurnik K. Niedermolekulare Heparine in der Pädiatrie. Hämostaseologie 2001;21:118-124
36. Nohe N, Flemmer A, Rumler R, Praum M, Auberger K. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 4 cases. Eur J Pediatr 1999;158:S134-S139
37. Massicotte MP, Julian J, Marzinotto VJ, et al. Dose finding and pharmacokinetics of prophylactic doses of a low molecular weight heparin (Reviparin™) in pediatric patients. Thromb Res 2003(in press)
38. Massicotte MP, Julian JA, Gent M, et al. The PROTEKT Study Group: an open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line related thrombotic complications in children: the PROTEKT trial. Thromb Res 2003;(in press)
39. Massicotte MP, Julian JA, Gent M, et al. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res 2003;(in press)
40. Sutor AH, Massicotte P, Leaker M, Andrew M. Heparin therapy in pediatric patients. Semin Thromb Hemost 1997;23:303-319
41. Massicotte MP. Low-molecular-weight heparin therapy in children. J Pediatr Hematol Oncol 2001;23:189-194
42. Greaves M. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 2002;87:163-164
43. Andrew M, deVeber G. Pediatric Thromboembolism and Stroke Protocols. Hamilton, BC: Dekker Inc.; 1999
44. Crowther MA, Berry LR, Monagle PT, Chan AK. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 2002;116:178-186
45. Albisetti M, Andrew M. Low molecular weight heparin in children. Eur J Pediatr 2002;161:71-77
46. Massicotte MP, Chan AKC, deVeber G, Monagle P. Venous thrombosis in children. J Thromb Haemost 2003;(in press)
47. Dimitrakakis C, Papageorgiou P, Papageorgiou I, Antzaklis A, Sakarelou N, Michalas S. Absence of transplacental passage of the low molecular weight heparin enoxaparin. Haemostasis 2000;30:243-248
48. Sorensen HT, Johnsen SP, Larsen H, Pedersen L, Nielsen GL, Moller M. Birth outcomes in pregnant women treated with low-molecular-weight heparin. Acta Obstet Gynaecol Scand 2000;79:655-659
49. deVeber G, Chan A, Monagle P, et al. Anticoagulation therapy in pediatric patients with sinovenous thrombosis: a cohort study. Arch Neurol 1998;55:1533-1537
50. Punzalan RC, Hillery CA, Montgomery RR, Scott CA, Gill JC. Low-molecular-weight heparin in thrombotic disease in children and adolescents. J Pediatr Hematol Oncol 2000;22:137-142
51. Dix D, Andrew M, Marzinotto V, et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 2000;136:439-445
52. Piquet P, Laporte-Simitsidis S, Mismetti P, Doubine S, Decousus H. Nadroparin (Fraxiparine) in paediatrics. Dosage nomogram validation after cardiac surgery. Thromb Haemost 2001;(suppl):P2325 (abst)
53. Sträter R, Kumik K, Heller C, Schobess R, Luigs P, Nowak-Göttl U. Aspirin versus low-dose low-molecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients: a prospective follow-up study. Stroke 2001;32:2554-2558
54. Hoffmann S, Knoefler R, Lorenz N, et al. Clinical experience with LMWH in pediatric patients. Thromb Res 2001;103:345-353
55. Elhasid R, Lanir N, Sharon R, et al. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis 2001;12:367-370
56. Roschitz B, Beitzke A, Gamillscheg A, et al. UHF bolus administration in comparison to subcutaneous low molecular weight heparin in pediatric cardiac catheterization. In: Scharrer I, Schramm W, eds. 32nd Hemophilia Symposium. Berlin: Springer; 2002:111-114